TL

Tilray Brands, Inc.

TLRYHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$821.3M
+4.1% YoY
Net Income
-$2.19B
-792.6% YoY
EBITDA
-$2.13B
-2820.7% YoY
Free Cash Flow
-$31.1M

Scan Results

Daily timeframe
DateIndicatorDetails
Jul 8CONFIRMED MACD Positive CrossoverHistogram +0.0028, positive momentum
RSI OversoldRSI 26.4, below 30, stock may be oversold
Jul 7CONFIRMED RSI OversoldRSI 29.2, below 30, stock may be oversold
MACD Positive CrossoverHistogram +0.0082, positive momentum
About Tilray Brands, Inc.

Part of the healthcare sector, Tilray Brands, Inc. (TLRY) is listed under Drug Manufacturers - Specialty & Generic. The $540.7M market capitalization puts TLRY squarely in small-cap range for its industry. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.

Key stats
Market Cap$540.7M
Fwd P/E17.10
EPS$-14.65
Beta1.90
52W Change-27.0%
ROE-63.2%
Analysis

The balance sheet looks solid with $425.7M in cash comfortably exceeding the $343.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$31.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -63.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $628.4M (2022) to $821.3M (2025), reflecting a 31% increase over the period.

A beta of 1.90 means TLRY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TLRY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms